Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 196

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Aducanumab: Appropriate Use Recommendations Update

Open access
Cummings, Jeffrey, Rabinovici, G.D., Atri, A., Aisen, P., Apostolova, L.G., Hendrix, S., Sabbagh, M., Selkoe, D., Weiner, M., Salloway, S. · 2022 · The Journal of Prevention of Alzheimer's Disease

Abstract

Aducanumab (Aduhelm) is approved in the United States for the treatment of patients with mild cognitive impairment due to Alzheimer's disease or mild AD dementia. Aducanumab Appropriate Use Recommendations (AURs) have been published and have helped guide best practices for use of aducanumab. As real-world use has occurred and more information has accrued, the AURs require refinement. We update the AURs to better inform appropriate patient selection and improve shared decision-making, safety monitoring, and risk mitigation in treated patients. Based on evolving experience we emphasize the importance of detecting past medical conditions that may predispose to amyloid related imaging abnormalities (ARIA) or may increase the likelihood of ARIA complications including autoimmune or inflammatory conditions, seizures, or disorders associated with extensive white matter pathology. The apolipoprotein E ε4 (APOE4) genotype is strongly associated with ARIA and exhibits a gene dose effect. We recommend that clinicians perform APOE genotyping to better inform patient care decisions, discussions regarding risk, and clinician vigilance concerning ARIA. As most ARIA occurs during the titration period of aducanumab, we suggest performing MRI before the 5th, 7th, 9th, and 12th infusions to improve detection. Uncommonly, ARIA may be recurrent or serious; we suggest additional parameters for treatment discontinuation taking these observations into account. It is important to continue to learn from the real-world use of aducanumab and the AURs will continue to evolve as new information becomes available. This AUR update does not address efficacy, price, or insurance coverage and is provided to assist clinicians to establish best practices for use of aducanumab in the treatment of patients with mild cognitive impairment and mild Alzheimer's dementia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.14283/jpad.2022.34

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 17

  1. VandeVrede, 2020, Symptomatic amyloid-related imaging abnormalities in an APOE epsilon4/epsilon4 patient treated with aducanumab, Alzheimers Dement (Amst)., 12, e12101
  2. Barakos, 2022, Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer•s disease treated with anti-amyloid beta therapy, J Prev Alz Dis, 10.14283/jpad.2022.21 · DOI · Paper page
  3. Salvarani, 2013, Abeta-related angiitis: comparison with CAA without inflammation and primary CNS vasculitis, Neurology, 81, 1596, 10.1212/WNL.0b013e3182a9f545 · DOI · Paper page
  4. Folstein, 1975, “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, 12, 189, 10.1016/0022-3956(75)90026-6 · DOI · Paper page
  5. Asselin, 2022, Validation of an magnetic resonance imaging acquisition and review protocol for Alzheimer•s disease and related disorders, Can Assoc Radiol J., 70, 172, 10.1016/j.carj.2018.10.008 · DOI
  6. Zhou, 2020, The study on analysis of risk factors for severity of white matter lesions and its correlation with cerebral microbleeds in the elderly with lacunar infarction, Medicine (Baltimore)., 99, e18865, 10.1097/MD.0000000000018865 · DOI
  7. Sevigny, 2016, Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial, Alzheimer Dis Assoc Disord, 30, 1, 10.1097/WAD.0000000000000144 · DOI
  8. Degenhardt, 2016, Florbetapir F18 PET amyloid neuroimaging and characteristics in patients with mild and moderate Alzheimer dementia, Psychosomatics, 57, 208, 10.1016/j.psym.2015.12.002 · DOI · Paper page
  9. Johnson, 2013, Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer•s Association, Alzheimers Dement, 9, e1, 10.1016/j.jalz.2013.01.002 · DOI · Paper page
  10. Leuzy, 2022, Blood-based biomarkers for Alzheimer•s disease, EMBO Mol Med, 14, e14408, 10.15252/emmm.202114408 · DOI · Paper page
  11. Yang, 2018, Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE epsilon4 haplotype status: a community-based cohort study, Lancet Neurol, 17, 773, 10.1016/S1474-4422(18)30251-5 · DOI
  12. Largent, 2021, Disclosing genetic risk of Alzheimer•s disease to cognitively unimpaired older adults: indings from the study of knowledge and reactions to APOE testing (SOKRATES II), J Alzheimers Dis, 84, 1015, 10.3233/JAD-210675 · DOI
  13. Vears, 2021, Return of individual research results from genomic research: A systematic review of stakeholder perspectives, PLoS One, 16, e0258646, 10.1371/journal.pone.0258646 · DOI
  14. Green, 2009, Disclosure of APOE genotype for risk of Alzheimer•s disease, N Engl J Med, 361, 245, 10.1056/NEJMoa0809578 · DOI · Paper page
  15. Gaubert, 2021, Decision-making competence in patients with Alzheimer•s disease: a review of the literature, Neuropsychol Rev, 31, 267, 10.1007/s11065-020-09472-2 · DOI
  16. Chiong, 2021, Decisions with patients and families regarding aducanumab in Alzheimer disease, with recommendations for consent: AAN position statement, Neurology
  17. Schneider, 1997, Eligibility of Alzheimer•s disease clinic patients for clinical trials, J Am Geriatr Soc, 45, 923, 10.1111/j.1532-5415.1997.tb02960.x · DOI

Cited by

Metadata

Authors
Cummings, J., Rabinovici, G. D., Atri, A., Aisen, P., Apostolova, L. G., Hendrix, S., Sabbagh, M., Selkoe, D., Weiner, M., & Salloway, S.
Venue
The Journal of Prevention of Alzheimer's Disease
Publisher
Elsevier BV
Published
2022-04
Volume
9
Issue
2
Pages
221-230
ISSN
2274-5807 (ISSN-L)
OpenAlex
W4226454711
Cited by
196
References
23
FWCI
21.82
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.